Literature DB >> 8041531

A prospective study of symptomatic gallstones in women: relation with oral contraceptives and other risk factors.

F Grodstein1, G A Colditz, D J Hunter, J E Manson, W C Willett, M J Stampfer.   

Abstract

OBJECTIVE: To examine the relation between oral contraceptives (OCs), body mass index (BMI), weight change, alcohol use, parity, smoking, and symptomatic gallstones in women less than 45 years of age.
METHODS: In this prospective study, associations between the various self-reported exposures and symptomatic gallstones were assessed in 96,211 female United States nurses with 425 cases of gallstones, using multiple logistic regression.
RESULTS: We found little relation between ever-use of OCs and symptomatic gallstones (relative risk [RR] 1.2, 95% confidence interval [CI] 0.9-1.6), although there was a modest elevation in risk for long-term use (RR 1.5, 95% CI 1.0-2.2 for 10-14 years; RR 1.6, 95% CI 1.0-2.4 for 15 or more years). There was also an increased risk in current users of OCs (RR 1.6, 95% CI 1.1-2.4). The risk of symptomatic gallstones increased with increasing BMI and weight gain since age 18. Women with four or more births had an elevated risk of symptomatic gallstones (RR 2.0, 95% CI 1.3-3.2), and current cigarette smokers had a slightly higher risk than never-smokers (RR 1.3, 95% CI 1.0-1.7). The risk decreased with increasing alcohol intake.
CONCLUSION: We found no substantial increase in the risk of symptomatic gallstones among ever-OC users, although current and long-term users had somewhat elevated risks. Body mass index remains the strongest predictor of symptomatic gallstones among young women.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8041531

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  19 in total

Review 1.  Fortnightly review: gallbladder disease.

Authors:  M C Bateson
Journal:  BMJ       Date:  1999-06-26

2.  Oral contraceptives and the risk of gallbladder disease: a comparative safety study.

Authors:  Mahyar Etminan; Joseph A C Delaney; Brian Bressler; James M Brophy
Journal:  CMAJ       Date:  2011-04-18       Impact factor: 8.262

Review 3.  Body mass index, abdominal fatness and the risk of gallbladder disease.

Authors:  Dagfinn Aune; Teresa Norat; Lars J Vatten
Journal:  Eur J Epidemiol       Date:  2015-09-15       Impact factor: 8.082

4.  Gallstones and cholecystectomy in modern Britain.

Authors:  M C Bateson
Journal:  Postgrad Med J       Date:  2000-11       Impact factor: 2.401

5.  Smoking habits and gallbladder disease: a systematic review and meta-analysis study.

Authors:  V Papadopoulos; D Filippou; K Mimidis
Journal:  Hippokratia       Date:  2020 Oct-Dec       Impact factor: 0.471

6.  Suicide mortality in relation to dietary intake of n-3 and n-6 polyunsaturated fatty acids and fish: equivocal findings from 3 large US cohort studies.

Authors:  Alexander C Tsai; Michel Lucas; Olivia I Okereke; Eilis J O'Reilly; Fariba Mirzaei; Ichiro Kawachi; Alberto Ascherio; Walter C Willett
Journal:  Am J Epidemiol       Date:  2014-05-08       Impact factor: 4.897

Review 7.  Gallstones in patients with liver cirrhosis: incidence, etiology, clinical and therapeutical aspects.

Authors:  Monica Acalovschi
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

8.  A high cholecystectomy rate in a cohort of Mexican American women who are postpartum at the time of oral contraceptive pill initiation.

Authors:  Gretchen S Stuart; Jennifer H Tang; Stephen F Heartwell; Carolyn L Westhoff
Journal:  Contraception       Date:  2007-11       Impact factor: 3.375

Review 9.  New insights into the molecular mechanisms underlying effects of estrogen on cholesterol gallstone formation.

Authors:  Helen H Wang; Min Liu; Deborah J Clegg; Piero Portincasa; David Q-H Wang
Journal:  Biochim Biophys Acta       Date:  2009-07-06

10.  Ezetimibe prevents the formation of oestrogen-induced cholesterol gallstones in mice.

Authors:  Ornella de Bari; Helen H Wang; Piero Portincasa; Chang-Nyol Paik; Min Liu; David Q-H Wang
Journal:  Eur J Clin Invest       Date:  2014-11-04       Impact factor: 4.686

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.